Advancing insights into Lp(a) as a causal factor in CVD - PACE-CME

Advancing insights into Lpa as a causal factor in CVD

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Expert opinion on the SOUL study results
Expert opinion on the SOUL study results
ACC.25
Expert opinion on the SOUL study results
- Gina Lundberg, MD
What we can learn from registry data to improve lipid goal attainment
What we can learn from registry data to improve lipid goal attainment
Hyperlipidemia
What we can learn from registry data to improve lipid goal attainment
- Kausik Ray, MBChB, MD, MPhil
FCS and SHTG: Are We Meeting the Need?
FCS and SHTG: Are We Meeting the Need?
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
- Ira J. Goldberg, MD
- Kausik Ray, MBChB, MD, MPhil
- Christie Ballantyne, MD
0.25 credits
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
AHA 2024
Promising results with oral Lp(a) inhibitor in phase 2 trial
- Stephen Nicholls, FRACP, FACC, FESC, FAHA